Pharmacokinetics and tolerability of prefilled syringe and auto-injector presentations of MSB11456: results of a randomized, single-dose study in healthy adults

References

• World Health Organization (WHO). Prequalified Medicinal Products. Tocilizumab. Reference BT-CV001 (a). World Health Organization Prequalification Team (10 February 2022).
   Google Scholar
• Genentech. Actemra®(tocilizumab) injection, for intravenous or subcutaneous use. Highlights of prescribing information. 2022. South San Francisco (CA). [Online]. [cited 2023 Feb 6]. Available from: https://www.gene.com/download/pdf/actemra_prescribing.pdf
   Google Scholar
• Shetty A, Hanson R, Korsten P, et al. Tocilizumab in the treatment of rheumatoid arthritis and beyond. Drug Des Devel Ther. 2014;8:349–364.
   PubMed Web of Science ®Google Scholar
• Navarro-Millán I, Singh JA, Curtis JR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther. 2012 Apr;34(788–802.e3):788–802.e3.
   PubMedGoogle Scholar
• Schwabe C, Illes A, Ullmann M, et al. Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial. Expert Rev Clin Immunol. 2022;18:533–543.
   PubMed Web of Science ®Google Scholar
• Overton PM, Shalet N, Somers F, et al. Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: a Systematic Review. Patient Prefer Adherence. 2021;15:811–834.
   PubMed Web of Science ®Google Scholar
• Stoner KL, Harder H, Fallowfield LJ, et al. Intravenous versus Subcutaneous Drug Administration Which Do Patients Prefer? A Systematic Review. Patient 2014;8:145–153.
   Google Scholar
• Besada E. Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review. Patient Prefer Adherence. 2014;8:1051.
   PubMed Web of Science ®Google Scholar
• Dashiell-Aje E, Harding G, Pascoe K, et al. Patient Evaluation of Satisfaction and Outcomes with an Autoinjector for Self-Administration of Subcutaneous Belimumab in Patients with Systemic Lupus Erythematosus. Patient. 2018;11(1):119–129.
   PubMedGoogle Scholar
• Fettner S, Mela C, Wildenhahn F, et al. Evidence of bioequivalence and positive patient user handling of a tocilizumab autoinjector. Expert Opin Drug Deliv. 2019;16(5): 551–561.
   PubMed Web of Science ®Google Scholar
• Martin UJ, Fuhr R, Forte P, et al. Comparison of autoinjector with accessorized prefilled syringe for benralizumab pharmacokinetic exposure: AMES trial results. J Asthma. 2021;58(1): 93–101.
   PubMed Web of Science ®Google Scholar
• Hu P, Wang J, Florian J, et al. Systematic Review of Device Parameters and Design of Studies Bridging Biologic-Device Combination Products Using Prefilled Syringes and Autoinjectors. AAPS J. 2020;22(2). DOI:10.1208/s12248-020-0433-8.
   Web of Science ®Google Scholar
• Dua P, Hawkins E, Van Der Graaf P. A Tutorial on Target-Mediated Drug Disposition (TMDD) Models. CPT Pharmacometrics Syst Pharmacol. 2015;4(6):324–337.
   PubMedGoogle Scholar
• Smit C, De Hoogd S, Rjm B, et al. Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opin Drug Metab Toxicol. 2018;14(3):275–285.
   PubMed Web of Science ®Google Scholar
• Leung E, Crass RL, Jorgensen SCJ, et al. Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19. Clin Pharmacokinet. 2022;61(2):155–165.
   PubMed Web of Science ®Google Scholar
• Gradel AKJ, Porsgaard T, Lykkesfeldt J, et al. Factors Affecting the Absorption of Subcutaneously Administered Insulin: effect on Variability. J Diabetes Res. 2018;2018:1–17.
   Web of Science ®Google Scholar
• Sabet A, Dickerson DS, Kunina EE, et al. A Randomised Controlled Trial Comparing the Pharmacokinetics and Tolerability of the Proposed Adalimumab Biosimilar MSB11022 Delivered via Autoinjector and Pre-filled Syringe in Healthy Subjects. Rheumatol Ther. 2022;9(2):693–704.
   PubMed Web of Science ®Google Scholar
• Lon H-K, Cheng L, Nudurupati S, et al. Pharmacokinetic Comparability of Risankizumab Formulations in Prefilled Syringe and Auto-injector for Subcutaneous Injection. Clin Ther. 2021;43(3):629–636.
   PubMed Web of Science ®Google Scholar
• Stauffer VL, Sides R, Lanteri-Minet M, et al. Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies. Patient Prefer Adherence. 2018;12:1785–1795.
   PubMed Web of Science ®Google Scholar
• Ramael S, Moschetti V, Peter N, et al. AB0391 Similar pharmacokinetics, safety and tolerability of the Adalimumab biosimilar candidate BI 695501 administered subcutaneously via prefilled syringe (PFS) or autoinjector (AI) (Voltaire®-ai). BMJ. 2017;76:1185.
   Google Scholar
• Cherniakov I, Cohen‐Barak O, Tiver R, et al. A Pharmacokinetic Bioequivalence Study of Fremanezumab Administered Subcutaneously Using an Autoinjector and a Prefilled Syringe. Clin Pharmacol Drug Dev. 2021;10(9): 1018–1027.
   PubMed Web of Science ®Google Scholar
• Cohen YZ, Zhang X, Xia B, et al. Pharmacokinetics of Subcutaneous Dupilumab Injection with an Autoinjector Device or Prefilled Syringe. Clin Pharmacol Drug Dev. 2022;11:675–681.
   PubMed Web of Science ®Google Scholar
• Hupperts R, Becker V, Friedrich J, et al. Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction. Expert Opin Drug Deliv. 2015;12(1): 15–25.
   PubMed Web of Science ®Google Scholar